Credit: Better Therapeutics. AspyreRx is available in the Apple App and Google Play stores. AspyreRx™ is now available for use as a prescription digital behavioral therapeutic device for adults with ...

(RTTNews) - Shares of Better Therapeutics, Inc. (BTTX) gain 27% in the after-hour market after the company announced that it received FDA authorization for AspyreRx to treat adults with type 2 ...

In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c “This regulatory milestone signals a promising future where ...

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the ...

Right on schedule, after securing FDA de novo clearance for its digital therapeutic designed to help manage Type 2 diabetes, Better Therapeutics is beginning the commercial launch of the app. When it ...

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced top-line ...

Better days may have finally arrived for Better Therapeutics, after the company started this year with a swath of layoffs and sustained losses. Better announced Monday afternoon that it received a ...

A Better Therapeutics mobile app that digitizes cognitive behavioral therapy is now authorized by the FDA as a treatment for type to 2 diabetes, a regulatory decision that creates a new class of ...

Last week, Better Therapeutics, a company developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and diabetes management platform Glooko announced that they were ...

Digital therapeutics developer Click Therapeutics is building up its prospects in cardiometabolic disorders by acquiring the assets of Better Therapeutics, a company whose technology platform yielded ...

Over a lifetime horizon AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost Study suggests that ...

Pivotal trial established use of AspyreRx alongside standard of care demonstrating clinically meaningful and statistically significant reduction in HbA1c leading to FDA authorization In a subgroup ...